CorWave LVAS FIH Study (NCT06907017) | Clinical Trial Compass
RecruitingNot Applicable
CorWave LVAS FIH Study
Australia20 participantsStarted 2025-05-06
Plain-language summary
The study is a prospective, multi-center, non-randomized trial to evaluate the safety and effectiveness of the CorWave LVAS for the treatment of advanced heart failure patients.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subject or legal representative has signed Informed Consent Form
* Age \> 18 and \< 75 years old
* Body Surface Area (BSA) ≥ 1.2 m2
* Left Ventricular Ejection Fraction (LVEF) ≤ 35%
* Inotrope dependent OR
* Cardiac Index (CI) \< 2.2 L/min/m2, while not on inotropes and subjects must also meet one of the following criteria:
* On Guideline Directed Medical Therapy (GDMT) for at least 45 out of the last 60 days and are failing to respond.
* Advanced heart failure (Class III or Class IV for at least 14 days AND support from short term mechanical circulatory support for up to 7 days).
* Females of childbearing age must agree to use adequate contraception.
* Patient must be eligible for heart transplantation.
Exclusion Criteria:
* Heart failure (HF) due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis or restrictive cardiomyopathy.
* Technical obstacles which pose an inordinately high surgical risk, in the judgment of the Investigator
* Ongoing mechanical circulatory support (MCS) other than IABP or micro axial pumps
* INTERMACS Class I patients
* Subject is on a ventilator
* Subject is pregnant or breastfeeding
* Presence of a mechanical aortic valve that will not be converted to a bioprosthesis at the time of LVAD implant
* History of any organ transplant
* Platelet count \< 100,000/μl
* Psychiatric disease/disorder, illicit drug use, irreversible cognitive dysfunction or psychosocial is…
What they're measuring
1
Survival post-implant
Timeframe: 30 days
2
Freedom from adverse events associated with CorWave LVAD